System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Guilhem Roubaud is an expert in Oncology at Institut Bergonié (France). As of October 2026, ScienceLeadR ranks Guilhem Roubaud in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Genital Diseases, Male. Guilhem Roubaud has authored 227 publications, the most recent in 2026, and is an investigator in 38 clinical trials, 13 of them ongoing. SLR score: 1,220 (community average: 125). How the SLR is computed.

LeadR Profile

Guilhem Roubaud Institut Bergonié France
1 220 ScienceLeadR Reputation 1220

Unlock

Register Login
Network Map

Oncology

Subspecialties: Urology - Radiotherapy - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2010 - 2026
Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 227

Citations

Citations: 6 075 1st author: 13 Last author: 19 Unique author: 0

Main journals

J Clin Oncol 44
Ann Oncol 35
Eur J Cancer 11
Prog Urol 9
Cancer Radiother 8

Best Journals

J Clin Oncol 33
Ann Oncol 29
Lancet Oncol 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Digital Patient-Reported Monitoring of Functional Recovery After Robot-Assisted Radical Prostatectomy in High-Risk Prostate Cancer Treated With or Without Perioperative Hormonal Therapy.
PMID 42739177 — monitoring, ambulatory, androgens, neoplasms, prostate, rehabilitation, recycling, prostatic neoplasms, therapeutics, prostatectomy, digital health		Diagnostics (Basel)20261
Real-World Outcomes of [ 177Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer.
PMID 42562607 — safety, androgens, receptors, androgen, neoplasms, prostate, drug therapy, aged, neoplasm metastasis, prostatic neoplasms, nuclear medicine, castration, therapeutics, chemotherapy		J Nucl Med20260
Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making.
PMID 42459311 — research design, genes, recombination, genetic, homologous recombination, breast neoplasms, clinical decision-making, neoplasms, prostate, decision making, biomarkers, genes, neoplasm, recombinational dna repair, breast, prostatic neoplasms, therapeutics, genes, brca2, liquid biopsy		Front Oncol20260
Evidence Thresholds for Novel Therapeutic Strategies in Prostate Cancer: A Consensus Statement from the Prostate Cancer Committee of the French Urological Association.
PMID 42413772 — neoplasms, prostate, prostatic neoplasms, therapeutics		Fr J Urol20260
Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods.
PMID 41801644 — sunitinib, protein kinases, protein kinase inhibitors, pharmacology, work		Clin Pharmacokinet20260

Clinical Studies 38

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 1

By phase:

Phase 3 21
Phase 2 8
N/A 4
Phase 1/Phase 2 4
Phase 1 1

By status:

Completed 14
Recruiting 12
Active not recruiting 10
Terminated 2

By type:

Interventional 37
Observational 1

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 5
multicentricup10 28

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

13 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Test Inavolisib Treatment in Patients With Metastatic Castration Resistant Prostate Cancer
2025-521327-67-00 — safety, docetaxel, neoplasms, prostate, prostatic neoplasms, castration, therapeutics		Phase 2Recruiting2026
Pasritamig vs Placebo in late line Metastatic Castration resistant Prostate Cancer (mCRPC)
2025-520927-26-00 — cells, kallikreins, neoplasms, prostate, prostatic neoplasms, castration, t-lymphocytes		Phase 3Recruiting2025
A Study of an Intermittent ADT Approach with Apalutamide Monotherapy in Participants with mCSPC
2022-502686-24-00 — disease-free survival, androgens, neoplasms, prostate, prostatic neoplasms, castration, therapeutics, prospective studies		Phase 3Active not recruiting2023
AZD5305 vs Placebo in Men with Metastatic Castration Sensitive Prostate Cancer Receiving Physician s Choice New Hormonal Agents
2023-504214-30-00 — neoplasms, prostate, prostatic neoplasms, castration, men		Phase 3Active not recruiting2024
Talazoparib plus Enzalutamide after progression to prior ARPi in Metastatic Prostate Cancer
2023-510536-37-00 — androgens, receptors, androgen, neoplasms, prostate, prostatic neoplasms, castration, therapeutics		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS